First studies with neoadjuvant application of the PD1 inhibitor pembrolizumab in surgical resectable HNSCC indicate that response rates might be superior compared to the current second line use in cases refractory to platinum‐based systemic therapies and with exhausted surgical and radiation‐oncological treatment approaches.39, 40 As pembrolizumab inhibits PD‐L1 and PD‐L2 signaling, this might also be a promising drug for neoadjuvant OSCC treatment. Here, PDCD1LG2 is linked to head and neck squamous cell carcinoma.